Hutchison China MediTech, or Chi-Med, a domestic biopharmaceutical company, announced the China market launch of a novel drug to treat neuroendocrine tumors (NET) on Saturday.

The company also said a rolling submission of a new drug application of the oral capsule Surufatinib, an innovative oncology drug with independent research and development efforts, was initiated with the United States Food and Drug Administration in late December, and its marketing authorization application in Europe is being prepared.

In the US, the drug was granted fast track designation for the treatment of pancreatic and non-pancreatic neuroendocrine tumors in April 2020, the company said.

“Surufatinib has the potential to become the first approved therapy to address all NET patients regardless of the tumor origin. We look forward to realizing its potential in the domestic and global markets,” said Su Weiguo, Chi-Med’s chief scientific officer.

“Compared with other NET therapies available in the market, surufatinib has a unique dual mode of action by both inhibiting angiogenesis and promoting the body’s immune response against tumor cells. We believe the drug will be well received by the market,” he said.

Chen Kaixian, an academician with the Chinese Academy of Sciences, said the market launch of the medicine, the company’s second oncology drug approved in China, provides a new solution to neuroendocrine tumor treatment.

“It also showcases to the global medical community that China’s innovative drugs are accelerating to benefit patients in the country, and even the world, with cutting-edge research, standardized and rigorous R&D processes, and high levels of quality,” he said.

Su added that the enterprise’s philosophy is always to do early-stage R&D in China and conduct simultaneous clinical development globally “with an ultimate aim to address unmet medical needs and help patients all around the world”.

The global Phase III clinical trial of fruquintinib, the company’s first approved oncology drug in China, kicked off in September and is ongoing. The trial will enroll approximately 680 patients with metastatic colorectal cancer in the US, Europe and Japan, he said.

Medical experts explained that neuroendocrine tumors can happen to multiple organs, including the stomach, intestine, pancreas, and lung, and its incidence rate has been rising over past years in the country.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

China’s Q1 new loans reaches nearly 7t yuan to support virus-hit economy

BEIJING – China’s new loans have reached nearly 7 trillion yuan ($988 billion) in the first quarter of this year as the country steps up financial support to shore up the virus-hit economy, according to a senior banking official. This…

Energy firms to help vulnerable customers through Covid-19 outbreak

Gas and electricity suppliers will help up to four million vulnerable customers to make sure they do not get cut off during the coronavirus outbreak. Customers with pre-payment meters will receive financial help if they cannot leave the house to top…

James Moore Are insurance companies the emerging villains of the pandemic?

The insurance industry is rapidly emerging as a villain of the pandemic. Which? this morning has some petrol to pour onto a fire already raging as a result of claims getting denied because of our old friend small print, or…

Study: Russia’s Sputnik V vaccine appears safe, effective

MOSCOW — Russian scientists say the country’s Sputnik V vaccine appears safe and effective against COVID-19, according to early results of an advanced study published in a British medical journal. The news is a boost for the shot that is…